The Clinical Study on the Therapeutics of Cytokine-induced Killer Cells on the Patients with Advanced Non-small-cell Lung Cancer

Objective To observe the therapy effect of cytokine-induced killer(CIK)in PBMC of patients with advanced non-small-cell lung cancer.Methods CIK cells were induced and amplified from PBMC of 68 NSCLC patients by in vitro incuba- tion with IL-2,IFN-y,anti-CD3 monoclonal antibody for 11-14 days and then transfused back to patients.The changes of T cell and NK cell of patients before and after CIK cell treatment with FCM were tested.Results After 11-14 days culture,the total number of CIK cells and CD3~+,CD56~+ T cells expanded greatly.After being treated with CIK cells,the numbers of CD3,CD4 T cell and NK cells of patients increased significantly(P0.01).The clinical symptoms of 86 patients were improved clearly. Conclusion CIK cells may be expanded effectively from patients with advanced NSCLC.The adoptive immunotherapy of auto-im- munity of CIK cells can significantly enhance cellular immune function and improve the clinical symptom of patients.